Literature DB >> 9141202

Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.

H Maiwald1, W Jilg, H L Bock, T Löscher, F Sonnenburg.   

Abstract

Seventy-one anti-hepatitis A virus (HAV) negative volunteers were immunized against hepatitis A. An inactivated hepatitis A vaccine (HAVRIX, SmithKline Beecham), derived from tissue cell cultures, at single doses of 720 ELISA units was used following a schedule of vaccinations at month 0.1 and 6. The vaccines were tested for the presence of HAV antibodies 1 month after each vaccination and then after 2, 3, 4 and 5 years. The annual decrease of anti-HAV titres was 25%. Five years after vaccination a protective antibody titre, varying between 20 and 5200 mIU ml-1, could be demonstrated in all 47 retested volunteers with a geometric mean titre (GMT) of 442 mIU ml-1. Levels of anti-HAV-antibodies following active immunization were significantly higher in female volunteers. This could be consistently demonstrated throughout the observation period. Based on these data the antibody persistence was calculated over time. GMTs at protective levels higher than 20 mIU ml-1 can be expected to persist for at least 15 years.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141202     DOI: 10.1016/s0264-410x(97)00211-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 2.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

3.  Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children.

Authors:  Gregory A Raczniak; Timothy K Thomas; Lisa R Bulkow; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Vaccine       Date:  2013-03-05       Impact factor: 3.641

Review 4.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

5.  Do medical college students living in hostel in India need hepatitis A vaccine?

Authors:  Rahul Karna; Rajesh Ruttala; Premashis Kar
Journal:  Indian J Med Res       Date:  2018-08       Impact factor: 2.375

6.  The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults.

Authors:  Jiseun Lim; Yeong-Jun Song; Woong-Sub Park; Haesook Sohn; Moo-Sik Lee; Dong-Hoon Shin; Chun-Bae Kim; Hwasung Kim; Gyung-Jae Oh; Moran Ki
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

7.  Hepatitis A virus infections, immunisations and demographic determinants in children and adolescents, Germany.

Authors:  Kai Michaelis; Christina Poethko-Müller; Ronny Kuhnert; Klaus Stark; Mirko Faber
Journal:  Sci Rep       Date:  2018-11-12       Impact factor: 4.379

8.  Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.

Authors:  Yeong-Jun Song; Jiseun Lim; Woong-Sub Park; Haesook Sohn; Moo-Sik Lee; Dong-Hoon Shin; Chun-Bae Kim; Hwasung Kim; Gyung-Jae Oh; Moran Ki
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.